Back to News
Market Impact: 0.35
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
Source: benzinga.com
Healthcare & BiotechCompany FundamentalsCompany Fundamentals
Aptevo Therapeutics reported that mipletamig achieved a 93% clinical benefit rate in TP53-mutated frontline acute myeloid leukemia patients when given as triplet therapy. The headline efficacy result supports a favorable read-through for the lead program’s potential in a high-risk mutation subgroup.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
APVO0.75
More News
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- ‘How many canaries have we killed in the coal mine?’ — Wall Street debates if the latest AI bubble warnings are another head fake or the real thing
- Alphabet’s chief investment officer responds to Jefferies warning that the most likely outcome of the AI boom is massive U.S. capital destruction
- A 44-minute call and a memo: How Alexandr Wang won Mark Zuckerberg’s trust—and a $100 billion-plus AI bet
- TSMC posts a sixth straight record profit but turns cautious on 2027